SCHEMBL2062865

SCHEMBL2062865

COc1cc2c(Oc3ccc(CC(=O)Nc4ccc(C(F)(F)F)cc4)cc3)ccnc2cc1OCCC(N)C(=O)OC1CCCC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRA P16234 8/20 0.56
KIT P10721 7/20 0.56
CSF1R P07333 3/20 0.56
PDGFRB P09619 3/20 0.56
RET P07949 2/20 0.56
DDR1 Q08345 2/20 0.56
FLT3 P36888 3/20 0.51
FLT4 P35916 2/20 0.51
MET P08581 10/20 0.49
HDAC1 Q13547 2/20 0.49
KDR P35968 5/20 0.48
AURKA O14965 1/20 0.47
RIPK2 O43353 1/20 0.47
ABCB11 O95342 1/20 0.47
ABL1 P00519 1/20 0.47
EGFR P00533 1/20 0.47
ERBB2 P04626 1/20 0.47
NTRK1 P04629 1/20 0.47
LCK P06239 1/20 0.47
PGR P06401 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2062862 1.00 PDGFRA (0.56) PDGFRAKITCSF1RPDGFRBRET
SCHEMBL2063784 0.93 PDGFRA (0.55) PDGFRAKITCSF1RPDGFRBRET
SCHEMBL2063781 0.93 PDGFRA (0.55) PDGFRAKITCSF1RPDGFRBRET
SCHEMBL2064377 0.93 PDGFRA (0.55) PDGFRAKITCSF1RPDGFRBRET
SCHEMBL2064374 0.93 PDGFRA (0.55) PDGFRAKITCSF1RPDGFRBRET
SCHEMBL884376 0.93 PDGFRA (0.56) PDGFRAKITMETHDAC1KDR
SCHEMBL2062894 0.93 PDGFRA (0.56) PDGFRAKITMETHDAC1KDR
SCHEMBL884374 0.93 PDGFRA (0.56) PDGFRAKITMETHDAC1KDR
SCHEMBL2063568 0.91 PDGFRA (0.55) PDGFRAKITRETDDR1FLT3
SCHEMBL2063577 0.91 PDGFRA (0.55) PDGFRAKITRETDDR1FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148531-B2 Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity CHROMA THERAPEUTICS LTD. (GB) 2012-04-03 US disclosed
EP-1877383-B1 QUINOLINE AND QUINOXALINE DERIVATIVES AS INHIBITORS OF KINASE ENZYMATIC ACTIVITY CHROMA THERAPEUTICS LTD (GB) 2011-09-07 EP disclosed
US-20090131461-A1 Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity CHROMA THERAPEUTICS LTD. (GB) 2009-05-21 US disclosed
EP-1877383-A1 QUINOLINE AND QUINOXALINE DERIVATIVES AS INHIBITORS OF KINASE ENZYMATIC ACTIVITY Chroma Therapeutics Limited (GB) 2008-01-16 EP disclosed
WO-2006117552-A1 QUINOLINE AND QUINOXALINE DERIVATIVES AS INHIBITORS OF KINASE ENZYMATIC ACTIVITY CHROMA THERAPEUTICS LTD (GB) 2006-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131461-A1 Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity CDK1, AURKC, CSNK1G3 PDGFRA 3858/4885KIT 2291/4885CSF1R 3905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.